AffiliationDivision of Molecular and Clinical Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractDespite its status as the most commonly mutated oncogene in cancer, Ras has long been considered 'undruggable'. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.
CitationLindsay CR, Blackhall FH. Direct Ras G12C inhibitors: crossing the rubicon. Br J Cancer. 2019;121(3):197-8.
JournalBritish Journal of Cancer
- Improving Prospects for Targeting RAS.
- Authors: Singh H, Longo DL, Chabner BA
- Issue date: 2015 Nov 1
- KRAS: From undruggable to a druggable Cancer Target.
- Authors: Uprety D, Adjei AA
- Issue date: 2020 Sep
- Inhibitors of K-Ras plasma membrane localization.
- Authors: Cho KJ, van der Hoeven D, Hancock JF
- Issue date: 2013
- KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
- Authors: Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS
- Issue date: 2020 Mar
- After decades, progress against an 'undruggable' cancer target.
- Authors: Kaiser J
- Issue date: 2019 Nov 1